Potassium-Competitive Acid Blockers for Gastric Acid Hypersecretion
Solution Overview
Problem
There is an unmet need for safe and effective treatments for pathological hypersecretory conditions such as Zollinger-Ellison syndrome, which are not adequately addressed by proton pump inhibitors, and long-term use of which can lead to adverse effects.
Innovation Solution
Administration of potassium-competitive acid blockers (P-CABs), specifically compounds of formula (I) or fexuprazan, or their pharmaceutically acceptable salts, to treat conditions like Zollinger-Ellison syndrome, idiopathic gastric acid hypersecretion, and hypergastrinemia, reducing gastric acid secretion and associated symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If proton pump inhibitors are used to treat pathological hypersecretory conditions, then gastric acid secretion is reduced, but long-term use leads to adverse effects such as malabsorption of vitamin B12, iron, and calcium
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of acid-blocking compounds. Specifically, it introduces potassium-competitive acid blockers (P-CABs) with novel molecular structures (formula I and Ia) that differ from traditional PPIs in their mechanism of action and pharmacological properties, thereby achieving effective acid suppression without the adverse effects associated with long-term PPI use
Solution Approach 2:
The patent employs P-CABs as a temporary alternative to long-term PPI therapy. By using compounds with shorter half-lives and reversible binding mechanisms, the treatment achieves effective acid control during acute phases while avoiding the cumulative adverse effects of prolonged PPI exposure, allowing for de-prescribing when no longer needed
2Reliability
If proton pump inhibitors are used for long-term treatment, then gastric acid secretion is controlled, but risks include hypergastrinemia, pneumonia, dementia, and various drug interactions
Solution Approach 1:
The patent introduces P-CABs as an intermediary substance that blocks gastric acid secretion through a different mechanism than PPIs. By using potassium-competitive blockers that act reversibly on the H/K-ATPase enzyme, the treatment achieves acid control without triggering the cascade of adverse effects (hypergastrinemia, pneumonia, dementia) associated with prolonged PPI use
Solution Approach 2:
The patent inverts the approach by using reversible, competitive inhibition instead of irreversible binding. P-CABs compete with potassium for binding sites on H/K-ATPase, allowing the enzyme to function when the drug is not present, thereby avoiding the permanent or long-lasting effects seen with PPIs that irreversibly inhibit the enzyme
3Reliability
If proton pump inhibitors are used to treat Zollinger-Ellison syndrome, then acid overproduction is managed, but safety concerns arise with extended therapy
Solution Approach 1:
The patent applies parameter changes by using P-CABs with distinct pharmacokinetic and pharmacodynamic parameters compared to PPIs. The rapid onset, short duration, and reversible action of P-CABs allow for effective acid management in Zollinger-Ellison syndrome without the safety concerns of long-term PPI therapy, particularly in patients requiring extended treatment
Data Source
AI summary
The present application relates to compounds of formula (I) or (Ia) (e.g., fexuprazan), for treating pathological hypersecretory conditions, such as a condition comprising gastric acid hypersecretion (e.g., Zollinger-Ellison syndrome, idiopathic gastric acid hypersecretion, and/or hypergastrinemia).